ADVM
Income statement / Annual
Last year (2023), Adverum Biotechnologies, Inc.'s total revenue was $3.60 M,
and the percentage change from the previous year is not available.
In 2023, Adverum Biotechnologies, Inc.'s net income was -$117.17 M.
See Adverum Biotechnologies, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$3.60 M
|
$0.00
|
$7.50 M
|
$0.00
|
$250,000.00
|
$1.61 M
|
$1.85 M
|
$1.46 M
|
$2.32 M
|
$572,000.00
|
| Cost of Revenue |
$5.64 M |
$6.53 M |
$4.65 M |
$4.16 M |
$0.00 |
$0.00 |
$2.10 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$2.04 M |
-$6.53 M |
$2.86 M |
-$4.16 M |
$250,000.00 |
$1.61 M |
-$247,000.00 |
$1.46 M |
$2.32 M |
$572,000.00 |
| Gross Profit Ratio |
-0.57 |
0 |
0.38 |
0 |
1 |
1 |
-0.13 |
1 |
1 |
1 |
| Research and Development
Expenses |
$77.68 M
|
$99.28 M
|
$89.18 M
|
$73.31 M
|
$40.42 M
|
$50.13 M
|
$39.84 M
|
$31.67 M
|
$25.46 M
|
$16.98 M
|
| General & Administrative
Expenses |
$49.92 M
|
$57.86 M
|
$64.44 M
|
$44.64 M
|
$28.38 M
|
$24.56 M
|
$20.86 M
|
$24.36 M
|
$22.11 M
|
$8.00 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$49.92 M
|
$57.86 M
|
$64.44 M
|
$44.64 M
|
$28.38 M
|
$24.56 M
|
$20.86 M
|
$24.36 M
|
$22.11 M
|
$8.00 M
|
| Other Expenses |
$0.00 |
$2.67 M |
$582,000.00 |
$1.56 M |
$4.06 M |
$4.20 M |
$2.70 M |
$762,000.00 |
$370,000.00 |
-$1.00 M |
| Operating Expenses |
$127.59 M |
$157.14 M |
$153.62 M |
$117.95 M |
$68.80 M |
$74.69 M |
$60.70 M |
$56.03 M |
$47.57 M |
$24.97 M |
| Cost And Expenses |
$127.59 M |
$157.14 M |
$153.62 M |
$117.95 M |
$68.80 M |
$74.69 M |
$60.70 M |
$56.03 M |
$47.57 M |
$24.97 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$18,000.00 |
| Depreciation &
Amortization |
$5.64 M
|
$6.53 M
|
$4.65 M
|
$4.16 M
|
$1.57 M
|
$1.75 M
|
$2.10 M
|
$1.60 M
|
$812,000.00
|
$162,000.00
|
| EBITDA |
-$112.60 M
|
-$147.93 M
|
-$140.90 M
|
-$112.24 M
|
-$62.91 M
|
-$72.13 M
|
-$54.05 M
|
-$52.97 M
|
-$46.74 M
|
-$25.22 M
|
| EBITDA Ratio |
-31.28 |
0 |
-18.86 |
0 |
-267.89 |
-41.15 |
-30.69 |
4.22 |
-18.4 |
-42.66 |
| Operating Income Ratio
|
-34.39
|
0
|
-19.48
|
0
|
-274.18
|
-48.44
|
-31.83
|
-79.23
|
-20.62
|
-42.66
|
| Total Other
Income/Expenses Net |
$5.55 M
|
$549,000.00
|
-$481,000.00
|
$1.56 M
|
$4.06 M
|
-$796,000.00
|
$2.70 M
|
-$62.13 M
|
-$2.10 M
|
-$1.00 M
|
| Income Before Tax |
-$118.24 M |
-$154.46 M |
-$145.54 M |
-$116.39 M |
-$64.49 M |
-$73.88 M |
-$56.15 M |
-$114.52 M |
-$47.45 M |
-$25.40 M |
| Income Before Tax Ratio
|
-32.85
|
0
|
-19.41
|
0
|
-257.94
|
-45.83
|
-30.37
|
-78.71
|
-20.46
|
-44.41
|
| Income Tax Expense |
-$1.08 M |
$74,000.00 |
$4.41 M |
$1.11 M |
$1.40 M |
-$1.25 M |
$0.00 |
-$775,000.00 |
$1.76 M |
-$162,000.00 |
| Net Income |
-$117.17 M |
-$154.54 M |
-$145.54 M |
-$117.51 M |
-$64.49 M |
-$72.63 M |
-$56.15 M |
-$113.75 M |
-$47.45 M |
-$25.40 M |
| Net Income Ratio |
-32.55 |
0 |
-19.41 |
0 |
-257.94 |
-45.05 |
-30.37 |
-78.18 |
-20.46 |
-44.41 |
| EPS |
-11.62 |
-15.57 |
-14.85 |
-13.8 |
-10.06 |
-1.18 |
-1.29 |
-3.14 |
-1.86 |
-1.12 |
| EPS Diluted |
-11.62 |
-15.57 |
-14.85 |
-13.8 |
-10.06 |
-1.18 |
-1.29 |
-3.14 |
-1.84 |
-1.12 |
| Weighted Average Shares
Out |
$10.08 M
|
$9.93 M
|
$9.80 M
|
$8.51 M
|
$6.41 M
|
$61.38 M
|
$43.66 M
|
$36.25 M
|
$25.48 M
|
$22.75 M
|
| Weighted Average Shares
Out Diluted |
$10.08 M
|
$9.93 M
|
$9.80 M
|
$8.51 M
|
$6.41 M
|
$61.38 M
|
$43.66 M
|
$36.25 M
|
$25.86 M
|
$22.75 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
